Pharmacologic Substance – Page 4

J&J brushes off tariff headwinds with raised forecast, oncology surge

1 week ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

Sanofi backs $90M financing for I&I biologic developer

1 week ago talkbio0Tagged financing characteristics, I&I, sanofi, Series

sanofi, Series, financing characteristics, II

Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition

1 week ago talkbio0Tagged Camzyos, Clinical Trials, Hypertrophic Cardiomyopathy, Hypertrophic cardiomyopathy without obstruction, Myers, Obstructed

Camzyos, Hypertrophic Cardiomyopathy, Myers, Hypertrophic cardiomyopathy without obstruction, Obstructed, Clinical Trials

Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly

1 week ago talkbio0Tagged Alzheimer, Apolipoprotein E4, ARIA, authorization, Biogen, Eisai, Eli Lilly, EU, High, Kisunla, Leqembi, Restricted

Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High

Merck inks $493M biobucks deal to use Cyprumed’s tech to create oral peptides

1 week ago talkbio0Tagged biobucks, Cyprumed, Merck, Peptides

Cyprumed, Merck, biobucks, Peptides

Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives

1 week ago talkbio0Tagged 90%, Interleukin-2, Mural, Mural Oncology, Nemvaleukin Alfa, strategic alternatives

Interleukin-2, Mural Oncology, Mural, strategic alternatives, Nemvaleukin Alfa, 90%

Vaccine-probiotic combo prevents, clears bacterial gut infections in mice in antibiotic alternative test

1 week ago talkbio0Tagged Antibiotics, House mice, Immune response, Probiotics, Vaccines

Antibiotics, Probiotics, House mice, Immune response, Vaccines

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

1 week ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.

Ironwood Pharmaceuticals’ Stock Plummets Following Layoffs and FDA Setback for Apraglutide

1 week ago talkbio0Tagged Biotechnology, Goldman Sachs, Ironwood, Phase 3 Clinical Trials, plunge, regulatory hurdle, Short Bowel Syndrome, strategic alternatives, United States Food and Drug Administration

Ironwood Pharmaceuticals , apraglutide , short bowel syndrome (SBS) , Phase III trial , layoffs , FDA regulatory hurdle , stock plunge , strategic alternatives , Goldman Sachs , biotechnology

PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics

1 week ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Drug Discovery, Efficiency, Elix, mimetics, PepMetics, Peptides, pharmaceutical innovation, PRISM BioLab, Protein-Protein Interaction, small molecule inhibitors

PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation